Bio Special WhitePaper

Patent Rulings That Decided Who Could Launch What in APAC in 2026

Every December, generic and biosimilar teams across Asia Pacific sit down to fix their launch calendars for the coming year. The regulatory side of that ex...

 November 19, 2026 | Analysis

The 10 New Drugs Japan Expects to Sell Most: Peak-Sales Forecasts From Every 2026 NHI Listing Round

On 13 November, 16 new medicines joined Japan's National Health Insurance (NHI) price list. It was the last of the seven listing rounds Japan now runs each...

 November 18, 2026 | Analysis

Sold, Closed or Mothballed: 19 APAC Drug Manufacturing Sites That Changed Hands or Shut in 2026

Openings in this region arrive with ceremony. There is a groundbreaking, a ribbon, a minister and a press release with a capacity figure in the headline. E...

 November 18, 2026 | Analysis

2026 Drug Approvals: How the FDA, China, Japan and Europe Compare

For most of the last two decades, a year in drug approvals could be summarised in a single number: how many new molecular entities the US Food and Drug Adm...

 November 17, 2026 | Analysis

FDA Breakthrough Therapy Designation 2026: Three APAC-Originated Drugs Made the List, and None of Them Came From China

The record, counted to 14 November 2026. Method What counts An FDA Breakthrough Therapy designation disclosed by the sponsor or a licensee i...

 November 16, 2026 | Analysis

The 10 APAC Universities and Institutes Turning Research Into Licensed Drug Assets

Every November, the same ritual plays out in a European convention hall. University technology-transfer offices arrive with slides counting patents filed, ...

 November 11, 2026 | Analysis

10 APAC Biomanufacturing Plants Scheduled to Come Online Before End-2027, and How Many Have Already Slipped

Every capacity plan written in an Asian biopharma company this quarter rests on a calendar it did not write. Somewhere in the spreadsheet is an assumption ...

 November 10, 2026 | News

APAC Antibody-Drug Conjugates Past Phase 2, and Who Owns Them Now

Seventeen of them have already been licensed outside their home market, and the companies that will sell most of them in the US and Europe are Merck, Astra...

 November 05, 2026 | Analysis

Japan's FY2027 Off-Year Drug Price Revision: 8 Numbers That Decide Who Pays

Japan's off-year drug price revision stopped being a question of whether some time ago. When the health and finance ministers closed the FY2026 budget roun...

 October 29, 2026 | Analysis

17 APAC-Made Biosimilars Approved in the US or EU in 2026

Seventeen times in 2026, the US Food and Drug Administration or the European Commission cleared a biosimilar that was developed or made in Asia-Pacific. Ni...

 October 28, 2026 | Analysis

Orphan Drug Incentives in 9 APAC Markets, Compared

Every January, regulatory affairs teams across Asia-Pacific rebuild the same spreadsheet. Which markets will designate this asset as an orphan? Which will ...

 October 27, 2026 | Analysis

What Eight APAC Regulators Have Actually Published on AI in Drug Development

Ask a regulatory affairs lead in Tokyo, Seoul or Singapore what the rules are for using a machine learning model in a drug submission, and the honest answe...

 October 22, 2026 | Analysis

FDA Warning Letters to APAC Drug Facilities in Fiscal 2026: The Full Ledger, Normalised

Every October, the same headline writes itself. India leads the count of US FDA warning letters to Asian drug plants, China follows, and the rest of the re...

 October 21, 2026 | Analysis

The PD-(L)1 x VEGF Bispecific Race: Every APAC Programme in the Clinic, Counted

When the ESMO Congress opens in Madrid on 23 October, one drug class will be hard to miss. Two days in, on the evening of Sunday 25 October, the Presidenti...

 October 16, 2026 | Analysis


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close